Endo International PLC banner
E

Endo International PLC
LSE:0Y5F

Watchlist Manager
Endo International PLC
LSE:0Y5F
Watchlist
Price: 1 038.82 USD 3.04% Market Closed
Market Cap: $233.1B

Multiples-Based Value

There is not enough data to reliably calculate the multiples-based value of 0Y5F.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

0Y5F Multiples-Based Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

0Y5F Competitors Multiples
Endo International PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
Endo International PLC
LSE:0Y5F
244.4B USD 105.4 -83.6 386.8 970
US
Eli Lilly and Co
NYSE:LLY
887.6B USD 13.6 43 29 31
US
Johnson & Johnson
NYSE:JNJ
574.2B USD 6.1 21.4 14.9 18.3
UK
AstraZeneca PLC
LSE:AZN
236.2B GBP 5.3 30.6 16.9 23.8
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.1 19.6 11.6 13
US
Merck & Co Inc
NYSE:MRK
300.5B USD 4.6 16.5 10.2 12.4
CH
Novartis AG
SIX:NOVN
234.4B CHF 5.2 21 13 16.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.5 10.5 7.8 9.1
US
Pfizer Inc
NYSE:PFE
153.1B USD 2.4 19.7 7.6 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
118B USD 2.5 16.7 7.1 8.7
UK
GlaxoSmithKline PLC
LSE:GSK
88.7B GBP 2.7 15.5 8.4 10.4
P/E Multiple
Earnings Growth PEG
IE
E
Endo International PLC
LSE:0Y5F
Average P/E: 21.4
Negative Multiple: -83.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
43
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.4
7%
3.1
UK
AstraZeneca PLC
LSE:AZN
30.6
26%
1.2
CH
Roche Holding AG
SIX:ROG
19.6
14%
1.4
US
Merck & Co Inc
NYSE:MRK
16.5
14%
1.2
CH
Novartis AG
SIX:NOVN
21
14%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
1%
10.5
US
Pfizer Inc
NYSE:PFE
19.7
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.7
16%
1
UK
GlaxoSmithKline PLC
LSE:GSK
15.5
14%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IE
E
Endo International PLC
LSE:0Y5F
Average EV/EBITDA: 46.7
386.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
29
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
14.9
2%
7.4
UK
AstraZeneca PLC
LSE:AZN
16.9
13%
1.3
CH
Roche Holding AG
SIX:ROG
11.6
6%
1.9
US
Merck & Co Inc
NYSE:MRK
10.2
3%
3.4
CH
Novartis AG
SIX:NOVN
13
5%
2.6
DK
Novo Nordisk A/S
CSE:NOVO B
7.8
1%
7.8
US
Pfizer Inc
NYSE:PFE
7.6
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A
UK
GlaxoSmithKline PLC
LSE:GSK
8.4
3%
2.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IE
E
Endo International PLC
LSE:0Y5F
Average EV/EBIT: 102.1
970
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.3
6%
3
UK
AstraZeneca PLC
LSE:AZN
23.8
21%
1.1
CH
Roche Holding AG
SIX:ROG
13
6%
2.2
US
Merck & Co Inc
NYSE:MRK
12.4
6%
2.1
CH
Novartis AG
SIX:NOVN
16.7
9%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.6
US
Pfizer Inc
NYSE:PFE
10.1
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.7
-7%
N/A
UK
GlaxoSmithKline PLC
LSE:GSK
10.4
5%
2.1
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett